Researchers at the University of Virginia School of Medicine have developed a promising new antibiotic to treat potentially deadly gastrointestinal infections without harming the beneficial probiotic bacteria that help prevent relapse.The investigational drug, Amixicile, can take down even hyper-virulent strains of drug-resistant Clostridium difficile – commonly called "C. diff" – which kills 14,000 Americans each year. It also shows efficacy against Cryptosporidium (protozoans that cause diarrhea) and Helicobacter pylori in mouse models of infection and potentially against many other human pathogens, including Campylobacter jejuni.
No comments:
Post a Comment